EP MedSystems settlement
This article was originally published in The Gray Sheet
Executive SummaryCardiac electrophysiology device firm pays the U.S. Department of the Treasury $33,000 to resolve charges that it sold products to restricted countries including Iran in 2004 and earlier without governmental authorization. With the March 28 settlement, under which the firm does not admit guilt, EP MedSystems deems the related issues to be "closed." The company paid $244,000 to settle with the U.S. Department of Commerce last November (1"The Gray Sheet" Nov. 13, 2006, In Brief)...
You may also be interested in...
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.